Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 470

1.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. No abstract available.

2.

A mutation in the endonuclease domain of mouse MLH3 reveals novel roles for MutLγ during crossover formation in meiotic prophase I.

Toledo M, Sun X, Brieño-Enríquez MA, Raghavan V, Gray S, Pea J, Milano CR, Venkatesh A, Patel L, Borst PL, Alani E, Cohen PE.

PLoS Genet. 2019 Jun 6;15(6):e1008177. doi: 10.1371/journal.pgen.1008177. [Epub ahead of print]

3.

PXE, a Mysterious Inborn Error Clarified.

Borst P, Váradi A, van de Wetering K.

Trends Biochem Sci. 2019 Feb;44(2):125-140. doi: 10.1016/j.tibs.2018.10.005. Epub 2018 Nov 13. Review.

PMID:
30446375
4.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):950-952.

5.

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

Duarte AA, Gogola E, Sachs N, Barazas M, Annunziato S, R de Ruiter J, Velds A, Blatter S, Houthuijzen JM, van de Ven M, Clevers H, Borst P, Jonkers J, Rottenberg S.

Nat Methods. 2018 Feb;15(2):134-140. doi: 10.1038/nmeth.4535. Epub 2017 Dec 11.

PMID:
29256493
6.

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.

Pajic M, Blatter S, Guyader C, Gonggrijp M, Kersbergen A, Küçükosmanoğlu A, Sol W, Drost R, Jonkers J, Borst P, Rottenberg S.

Clin Cancer Res. 2017 Nov 15;23(22):7020-7033. doi: 10.1158/1078-0432.CCR-17-1279. Epub 2017 Aug 18.

7.

Maxi-circles, glycosomes, gene transposition, expression sites, transsplicing, transferrin receptors and base J.

Borst P.

Mol Biochem Parasitol. 2016 Jan-Feb;205(1-2):39-52. doi: 10.1016/j.molbiopara.2016.03.008. Epub 2016 Mar 26. Review.

PMID:
27021571
8.

HELB Is a Feedback Inhibitor of DNA End Resection.

Tkáč J, Xu G, Adhikary H, Young JTF, Gallo D, Escribano-Díaz C, Krietsch J, Orthwein A, Munro M, Sol W, Al-Hakim A, Lin ZY, Jonkers J, Borst P, Brown GW, Gingras AC, Rottenberg S, Masson JY, Durocher D.

Mol Cell. 2016 Feb 4;61(3):405-418. doi: 10.1016/j.molcel.2015.12.013. Epub 2016 Jan 7.

9.

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.

Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, Kucukosmanoglu A, Xu G, Voss FK, Reincke SM, Stauber T, Blomen VA, Vis DJ, Wessels LF, Brummelkamp TR, Borst P, Rottenberg S, Jentsch TJ.

EMBO J. 2015 Dec 14;34(24):2993-3008. doi: 10.15252/embj.201592409. Epub 2015 Nov 3.

10.

ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs.

Jansen RS, Mahakena S, de Haas M, Borst P, van de Wetering K.

J Biol Chem. 2015 Dec 18;290(51):30429-40. doi: 10.1074/jbc.M115.692103. Epub 2015 Oct 29.

11.

N-lactoyl-amino acids are ubiquitous metabolites that originate from CNDP2-mediated reverse proteolysis of lactate and amino acids.

Jansen RS, Addie R, Merkx R, Fish A, Mahakena S, Bleijerveld OB, Altelaar M, IJlst L, Wanders RJ, Borst P, van de Wetering K.

Proc Natl Acad Sci U S A. 2015 May 26;112(21):6601-6. doi: 10.1073/pnas.1424638112. Epub 2015 May 11.

12.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

13.

Defining the sequence requirements for the positioning of base J in DNA using SMRT sequencing.

Genest PA, Baugh L, Taipale A, Zhao W, Jan S, van Luenen HG, Korlach J, Clark T, Luong K, Boitano M, Turner S, Myler PJ, Borst P.

Nucleic Acids Res. 2015 Feb 27;43(4):2102-15. doi: 10.1093/nar/gkv095. Epub 2015 Feb 6.

14.

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.

Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.

15.

ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report.

Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Váradi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1985-9. doi: 10.1161/ATVBAHA.114.304017. Epub 2014 Jun 26.

PMID:
24969777
16.

ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release.

Jansen RS, Küçükosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20206-11. doi: 10.1073/pnas.1319582110. Epub 2013 Nov 25.

17.

P-glycoprotein ABCB1: a major player in drug handling by mammals.

Borst P, Schinkel AH.

J Clin Invest. 2013 Oct;123(10):4131-3. doi: 10.1172/JCI70430. Epub 2013 Oct 1.

18.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

19.

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S.

PLoS One. 2012;7(9):e45248. doi: 10.1371/journal.pone.0045248. Epub 2012 Sep 17.

20.

Glucosylated hydroxymethyluracil, DNA base J, prevents transcriptional readthrough in Leishmania.

van Luenen HG, Farris C, Jan S, Genest PA, Tripathi P, Velds A, Kerkhoven RM, Nieuwland M, Haydock A, Ramasamy G, Vainio S, Heidebrecht T, Perrakis A, Pagie L, van Steensel B, Myler PJ, Borst P.

Cell. 2012 Aug 31;150(5):909-21. doi: 10.1016/j.cell.2012.07.030.

21.

Binding of the J-binding protein to DNA containing glucosylated hmU (base J) or 5-hmC: evidence for a rapid conformational change upon DNA binding.

Heidebrecht T, Fish A, von Castelmur E, Johnson KA, Zaccai G, Borst P, Perrakis A.

J Am Chem Soc. 2012 Aug 15;134(32):13357-65. doi: 10.1021/ja303423t. Epub 2012 Jul 31.

PMID:
22775585
22.

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.

Zander SA, Kersbergen A, Sol W, Gonggrijp M, van de Wetering K, Jonkers J, Borst P, Rottenberg S.

Cancer Prev Res (Phila). 2012 Aug;5(8):1053-60. doi: 10.1158/1940-6207.CAPR-12-0050. Epub 2012 Jul 5.

24.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.

Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.

25.

Drug resistance in the mouse cancer clinic.

Rottenberg S, Borst P.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):81-9. doi: 10.1016/j.drup.2012.01.001. Epub 2012 Feb 14. Review.

26.

ABCC6 does not transport vitamin K3-glutathione conjugate from the liver: relevance to pathomechanisms of pseudoxanthoma elasticum.

Fülöp K, Jiang Q, Wetering KV, Pomozi V, Szabó PT, Arányi T, Sarkadi B, Borst P, Uitto J, Váradi A.

Biochem Biophys Res Commun. 2011 Nov 25;415(3):468-71. doi: 10.1016/j.bbrc.2011.10.095. Epub 2011 Oct 28.

27.

Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assays.

Krumpochova P, Sapthu S, Brouwers JF, de Haas M, de Vos R, Borst P, van de Wetering K.

FASEB J. 2012 Feb;26(2):738-47. doi: 10.1096/fj.11-195743. Epub 2011 Oct 27.

28.

Mammalian BTBD12 (SLX4) protects against genomic instability during mammalian spermatogenesis.

Holloway JK, Mohan S, Balmus G, Sun X, Modzelewski A, Borst PL, Freire R, Weiss RS, Cohen PE.

PLoS Genet. 2011 Jun;7(6):e1002094. doi: 10.1371/journal.pgen.1002094. Epub 2011 Jun 2.

29.

The structural basis for recognition of base J containing DNA by a novel DNA binding domain in JBP1.

Heidebrecht T, Christodoulou E, Chalmers MJ, Jan S, Ter Riet B, Grover RK, Joosten RP, Littler D, van Luenen H, Griffin PR, Wentworth P Jr, Borst P, Perrakis A.

Nucleic Acids Res. 2011 Jul;39(13):5715-28. doi: 10.1093/nar/gkr125. Epub 2011 Mar 16.

30.

Do predictive signatures really predict response to cancer chemotherapy?

Borst P, Wessels L.

Cell Cycle. 2010 Dec 15;9(24):4836-40. Epub 2010 Dec 15. Review.

PMID:
21150277
31.

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.

Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, Rottenberg S.

Cell Cycle. 2010 Sep 15;9(18):3780-91. Epub 2010 Sep 13.

32.

Mammalian BLM helicase is critical for integrating multiple pathways of meiotic recombination.

Holloway JK, Morelli MA, Borst PL, Cohen PE.

J Cell Biol. 2010 Mar 22;188(6):779-89. doi: 10.1083/jcb.200909048.

33.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S.

Cancer Res. 2010 Feb 15;70(4):1700-10. doi: 10.1158/0008-5472.CAN-09-3367. Epub 2010 Feb 9.

34.

Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin.

Beedholm-Ebsen R, van de Wetering K, Hardlei T, Nexø E, Borst P, Moestrup SK.

Blood. 2010 Feb 25;115(8):1632-9. doi: 10.1182/blood-2009-07-232587. Epub 2009 Nov 6.

35.

Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.

Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, Borst P, Rottenberg S.

Cancer Res. 2009 Aug 15;69(16):6396-404. doi: 10.1158/0008-5472.CAN-09-0041. Epub 2009 Aug 4.

36.

Targeted metabolomics identifies glucuronides of dietary phytoestrogens as a major class of MRP3 substrates in vivo.

van de Wetering K, Feddema W, Helms JB, Brouwers JF, Borst P.

Gastroenterology. 2009 Nov;137(5):1725-35. doi: 10.1053/j.gastro.2009.06.052. Epub 2009 Jul 3.

PMID:
19577570
37.

Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol.

van de Wetering K, Burkon A, Feddema W, Bot A, de Jonge H, Somoza V, Borst P.

Mol Pharmacol. 2009 Apr;75(4):876-85. doi: 10.1124/mol.108.052019. Epub 2008 Dec 29.

PMID:
19114588
38.

Evidence that J-binding protein 2 is a thymidine hydroxylase catalyzing the first step in the biosynthesis of DNA base J.

Vainio S, Genest PA, ter Riet B, van Luenen H, Borst P.

Mol Biochem Parasitol. 2009 Apr;164(2):157-61. doi: 10.1016/j.molbiopara.2008.12.001. Epub 2008 Dec 9.

PMID:
19114062
39.

Mega-dose vitamin C as therapy for human cancer?

Borst P.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):E95; author reply E96. doi: 10.1073/pnas.0809328105. Epub 2008 Nov 24. No abstract available.

40.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

41.

Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.

de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, Beijnen J, Borst P.

Mol Cancer Ther. 2008 Sep;7(9):3092-102. doi: 10.1158/1535-7163.MCT-08-0427. Epub 2008 Sep 2.

42.

Base J: discovery, biosynthesis, and possible functions.

Borst P, Sabatini R.

Annu Rev Microbiol. 2008;62:235-51. doi: 10.1146/annurev.micro.62.081307.162750. Review.

PMID:
18729733
43.
44.

How do real tumors become resistant to cisplatin?

Borst P, Rottenberg S, Jonkers J.

Cell Cycle. 2008 May 15;7(10):1353-9. Epub 2008 Mar 17. Review.

PMID:
18418074
45.

What makes tumors multidrug resistant?

Borst P, Jonkers J, Rottenberg S.

Cell Cycle. 2007 Nov 15;6(22):2782-7. Epub 2007 Aug 23. Review.

PMID:
17998803
46.

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12117-22. Epub 2007 Jul 11.

47.

Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides.

van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, Borst P.

Mol Pharmacol. 2007 Aug;72(2):387-94. Epub 2007 May 7.

PMID:
17485564
48.

Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm.

Ono N, Van der Heijden I, Scheffer GL, Van de Wetering K, Van Deemter E, De Haas M, Boerke A, Gadella BM, De Rooij DG, Neefjes JJ, Groothuis TA, Oomen L, Brocks L, Ishikawa T, Borst P.

Biochem J. 2007 Aug 15;406(1):31-40.

49.

The protein that binds to DNA base J in trypanosomatids has features of a thymidine hydroxylase.

Yu Z, Genest PA, ter Riet B, Sweeney K, DiPaolo C, Kieft R, Christodoulou E, Perrakis A, Simmons JM, Hausinger RP, van Luenen HG, Rigden DJ, Sabatini R, Borst P.

Nucleic Acids Res. 2007;35(7):2107-15. Epub 2007 Mar 27.

50.

Bill Slater at 90.

Borst P.

IUBMB Life. 2007 Jan;59(1):48-9. No abstract available.

Supplemental Content

Support Center